Physician profile
Malak Isaac
NPI 1922130228
$1,817.32
in general payments reported to CMS, 2019-2025
14 companies · $643 in 2025
The $643 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.21 · 2023: $443 · 2024: $719 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,791 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,791.22 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $451.01 | 2023-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $288.42 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $255.41 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $249.20 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $147.21 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.19 | 2023-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $107.33 | 2023-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $55.85 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $53.28 | 2024-2025 | Gemtesa |
| Biogen, INC. | $24.88 | 2023 | Vumerity |
| Halozyme INC | $20.63 | 2023 | |
| Merck Sharp & Dohme LLC | $20.20 | 2025 | Gardasil 9, Capvaxive |
| Astellas Pharma US INC | $19.95 | 2023 | Veozah |
| Currax Pharmaceuticals LLC | $15.76 | 2023 | Contrave, Nexlizet, Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malak Isaac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.